Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | KCNH3 | Q9ULD8 | 2/20 | 0.61 |
| ▸ | DNM2 | P50570 | 9/20 | 0.56 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3299537 | 1.00 | KMT2A (0.67) | KMT2AKCNH3DNM2SLC29A1MAPT | |
| SCHEMBL3298608 | 1.00 | KMT2A (0.67) | KMT2AKCNH3DNM2SLC29A1MAPT | |
| SCHEMBL14441519 | 1.00 | KMT2A (0.67) | KMT2AKCNH3DNM2SLC29A1MAPT | |
| SCHEMBL8054465 | 1.00 | KMT2A (0.67) | KMT2AKCNH3DNM2SLC29A1MAPT | |
| SCHEMBL3298621 | 1.00 | KMT2A (0.67) | KMT2AKCNH3DNM2SLC29A1MAPT | |
| SCHEMBL14441528 | 1.00 | KMT2A (0.67) | KMT2AKCNH3DNM2SLC29A1MAPT | |
| SCHEMBL1032562 | 1.00 | KMT2A (0.67) | KMT2AKCNH3DNM2SLC29A1MAPT | |
| SCHEMBL7774845 | 0.98 | KMT2A (0.65) | KMT2AKCNH3DNM2SLC29A1MAPT | |
| SCHEMBL7776218 | 0.98 | KMT2A (0.65) | KMT2AKCNH3DNM2SLC29A1MAPT | |
| SCHEMBL2783126 | 0.98 | KMT2A (0.65) | KMT2AKCNH3DNM2SLC29A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026088005-A1 | PERSONAL PROTECTIVE EQUIPMENT, METHODS AND SYSTEMS OF USE THEREOF | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4694984-A1 | RESPIRATORY PROTECTION DEVICES AND METHODS OF MANUFACTURING THE SAME | 3M Innovative Properties Company (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4694999-A1 | FILTER MEDIA FOR FILTRATION DEVICES AND METHODS OF MAKING AND USING THE SAME | 3M Innovative Properties Company (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12552914-B2 | Substituted thiolate salt melt additives | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2026-02-17 | — | — | US | disclosed |
| US-12467174-B2 | Substituted benzimidazole melt additives | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2025-11-11 | — | — | US | disclosed |
| EP-4637956-A1 | SHIRRED FILTER MEDIA AND METHODS OF MAKING AND USING THE SAME | 3M Innovative Properties Company (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12420223-B2 | Composite non-woven fabric and article comprising same | TORAY ADVANCED MATERIALS KOREA INC. (KR) | 2025-09-23 | — | — | US | disclosed |
| US-12415150-B2 | Composite nonwoven fabric and article comprising same | TORAY ADVANCED MATERIALS KOREA INC. (KR) | 2025-09-16 | — | — | US | disclosed |
| US-12409401-B2 | Pleated filtration assembly comprising spunbonded prefilter | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2025-09-09 | — | — | US | disclosed |
| EP-4069899-B1 | AROMATIC-HETEROCYCLIC RING MELT ADDITIVES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-0565774-B1 | Process for preparing amide derivatives from halominotriazines and acid halides | CYTEC TECH CORP (US) | 2001-03-28 | — | — | EP | disclosed |
| EP-0933369-A1 | Tris-(omega-haloacyl)melamines | CYTEC TECHNOLOGY CORP. (US) | 1999-08-04 | — | — | EP | disclosed |
| EP-0933370-A1 | Tris-(2,2,6,6-tetramethyl-piperid-4-yl-aminocarbonyl)melamine | CYTEC TECHNOLOGY CORP. (US) | 1999-08-04 | — | — | EP | disclosed |
| EP-0933371-A1 | N-halo acid amides | CYTEC TECHNOLOGY CORP. (US) | 1999-08-04 | — | — | EP | disclosed |
| EP-0930303-A2 | A process for preparing isocyanate compounds from haloaminotriazines and acid halides | CYTEC TECHNOLOGY CORP. (US) | 1999-07-21 | — | — | EP | disclosed |
| US-5571915-A | Process for preparing amide derivatives from haloaminotriazines and acid halides | CYTEC TECHNOLOGY CORP. (US) | 1996-11-05 | — | — | US | disclosed |
| US-5405959-A | Haloaminotraizines and acid halides | CYTEC TECHNOLOGY CORP. (US) | 1995-04-11 | — | — | US | disclosed |
| US-5288865-A | Process for preparing amide derivatives from haloaminotriazines and acid halides | AMERICAN CYANAMID COMPANY (US) | 1994-02-22 | — | — | US | disclosed |
| EP-0565774-A2 | Process for preparing amide derivatives from halominotriazines and acid halides | CYTEC TECHNOLOGY CORP. (US) | 1993-10-20 | — | — | EP | disclosed |
| EP-0541966-A2 | Process for preparing amide derivatives from halomines and acid halides | AMERICAN CYANAMID COMPANY (US) | 1993-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552914-B2 | Substituted thiolate salt melt additives | FRG1, EXOSC4, SCNN1G | KMT2A 1772/4885KCNH3 1231/4885DNM2 2863/4885 |
| US-12467174-B2 | Substituted benzimidazole melt additives | SMARCA4, BRD4, ARID2 | KMT2A 341/4885KCNH3 2331/4885DNM2 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.